SMART-DECISION: Discontinuing beta-blocker therapy was found to be noninferior to continuing the therapy among stable, low-risk patients who took it for at least one year following a #cvMI.

Get the latest insights from the #ACC26 LBCT: https://bit.ly/4bPRayM #CardioSky

TRI-FR at #ACC26: T-TEER in addition to standard-of-care medical therapy reduced the risk of death, #cvMI, stroke and hospitalization for #heartfailure compared with standard-of-care alone in patients with severe symptomatic #vhdTR.

Learn more: https://bit.ly/3PCWUVm #CardioSky

VESALIUS-CV results show evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or diabetes and without a previous #cvMI or #stroke compared with placebo.

Read more in our #AHA25 coverage: https://bit.ly/4oBNohQ

#CardioSky #MedSky

In the randomized PROCTOR trial, SVG #PCI was assoc with improved 1-yr clinical outcomes compared with native vessel PCI, primarily driven by lower rates of PCI-related MI & clinically driven target coronary territory #revascularization https://bit.ly/4ogyuxh

#TCT2025 #JACC #cvMI #cvCABG #CardioSky

Routine screening for H. pylori infection during hospitalization 🏥 for acute #cvMI did not significantly reduce bleeding events or improve clinical outcomes, based on findings from the HELP-MI SWEDEHEART trial presented at #ESCCongress. Get the details: 🔗 https://bit.ly/41TgxMb

Findings from the DUAL-ACS Trial presented at #ESCCongress suggest 3-month #DAPT has the potential for better survival & lower bleeding rates compared with 12-month DAPT following an acute #cvMI. Read more: https://bit.ly/4g2ihse

🎉 Congratulations to Mina Gachloo for her first presentation at the CVMI Workshop @ #CVPR 👏
In this work, we dive into the challenges of low-frame-rate cell tracking, where deep learning meets sparse temporal data. 🧵
#CVPR2025 #CVMI #CellTracking #BioImaging #DeepLearning

Delayed miR-199a Administration After Myocardial Infarction Precludes Pro-Regenerative Effects:

For clinical use, miR-199a-3p should be given early after #cvMI using non-viral delivery. Synthetic #miRNA mimics via lipofection show promise, but more research is needed. www.jacc.org/doi/10.1016/... #JACCBTS

10-Year Outcome of Complete or Infarct–Artery-Only Revascularization in STEMI with Multivessel Disease (DANAMI-3-PRIMULTI):

#EuroPCR #JACC LBCT: #FFR-guided complete #revascularization reduced future and repeated events compared with infarct-related artery only after 10 years. The risk was mainly driven by revasc, with no reduction in MIs or death. www.jacc.org/doi/10.1016/... #cvMI #revasc

Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry:

Myocardial infarction care pathways should implement early combination therapy with statins and #ezetimibe as standard care, because delaying use of combination LLT or using high-intensity statin monotherapy is associated with avoidable harm. www.jacc.org/doi/10.1016/...

#JACC #cvMI #SWEDEHEART

A #JACCAdvances updated network meta-analysis confirms that SAPT remains the safest choice for pts w/out indication for anticoagulation, significantly reducing 🩸 risk w/out 📈 mortality, #cvMI, or stroke risks. Personalized care remains essential. jacc.org/doi/10.1016/... #ACC25 @csilvers.bsky.social

RIVAWAR trial: Rivaroxaban was found to be as effective and safe as warfarin in resolving post #cvMI left ventricular thrombus at three months. #ACC25

Get full details here: bit.ly/4lf7XiS

#CardioSky #MedSky

Hot off the press - DAPA-MI finds patients with acute #cvMI experienced significant improvements in cardiometabolic outcomes after 1 yr compared w/ placebo; no significant benefits were observed in composite of CV death or hospitalization for #heartfailure #meded #medblue